Stephen J. Hoffman - Oct 10, 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role: Director
Signature: /s/ Martha Adler, Attorney-In-Fact
Stock symbol: ACRX
Transactions as of: Oct 10, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/13/2023, 04:35 PM
Previous filing: Jul 15, 2022
Next filing: Jun 24, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRX	Common Stock	Award	$0	+581	+31.63%	$0.00	2.42K	Oct 10, 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRX	Stock Option (Right to Buy)	Award	$0	+3.49K		$0.00	3.49K	Oct 10, 2023	Common Stock	3.49K	$0.68	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3	Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F4	100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.